Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 409 to 412 of 412 entries
Sorted by: Best Match Show Resources per page
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.

Hepatology (Baltimore, Md.)

Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, Sonika U, Dalal A.
PMID: 34822189
Hepatology. 2021 Nov 25; doi: 10.1002/hep.32255. Epub 2021 Nov 25.

BACKGROUND AND AIMS: Data on the use of intravenous L-ornithine L-aspartate (LOLA) in the treatment of overt HE (OHE) is limited. We evaluated the role of intravenous LOLA in patients of cirrhosis with OHE grade III-IV.APPROACH AND RESULTS: In...

Cite
Jain A, Sharma BC, Mahajan B, et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology. 2021;doi: 10.1002/hep.32255.
Jain, A., Sharma, B. C., Mahajan, B., Srivastava, S., Kumar, A., Sachdeva, S., Sonika, U., & Dalal, A. (2021). L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32255
Jain, Arpan, et al. "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32255
Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, Sonika U, Dalal A. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology. 2021 Nov 25; doi: 10.1002/hep.32255. Epub 2021 Nov 25. PMID: 34822189.
Copy Download .nbib Format: NLM
Saudi Arabian Society of Echocardiography Recommendations for Echocardiography Service During Corona Virus Disease 2019 (COVID-19) Outbreak.

Journal of the Saudi Heart Association

Ghazal S, Qaddoura F, Kinsara A, Omran A, Atiyah M, Al Refae M, Dalak F, Ahmari SA, Al Sehly A, Sahal N, Onazi A, Bader R.
PMID: 33329992
J Saudi Heart Assoc. 2020 May 18;32(5):1-5. doi: 10.37616/2212-5043.1038. eCollection 2020.

We are summarizing the recommendations for the use of Echocardiography in patients during COVID-19 pandemic. The patient risk for COVID-19 should be assessed according to the Saudi CDC guidelines. Echocardiography should only be performed of considered appropriate and will...

Cite
Ghazal S, Qaddoura F, Kinsara A, et al. Saudi Arabian Society of Echocardiography Recommendations for Echocardiography Service During Corona Virus Disease 2019 (COVID-19) Outbreak. J Saudi Heart Assoc. 2020;32(5):1-5doi: 10.37616/2212-5043.1038.
Ghazal, S., Qaddoura, F., Kinsara, A., Omran, A., Atiyah, M., Al Refae, M., Dalak, F., Ahmari, S. A., Al Sehly, A., Sahal, N., Onazi, A., & Bader, R. (2020). Saudi Arabian Society of Echocardiography Recommendations for Echocardiography Service During Corona Virus Disease 2019 (COVID-19) Outbreak. Journal of the Saudi Heart Association, 32(5), 1-5. https://doi.org/10.37616/2212-5043.1038
Ghazal, Sami, et al. "Saudi Arabian Society of Echocardiography Recommendations for Echocardiography Service During Corona Virus Disease 2019 (COVID-19) Outbreak." Journal of the Saudi Heart Association vol. 32,5 (2020): 1-5. doi: https://doi.org/10.37616/2212-5043.1038
Ghazal S, Qaddoura F, Kinsara A, Omran A, Atiyah M, Al Refae M, Dalak F, Ahmari SA, Al Sehly A, Sahal N, Onazi A, Bader R. Saudi Arabian Society of Echocardiography Recommendations for Echocardiography Service During Corona Virus Disease 2019 (COVID-19) Outbreak. J Saudi Heart Assoc. 2020 May 18;32(5):1-5. doi: 10.37616/2212-5043.1038. eCollection 2020. PMID: 33329992; PMCID: PMC7735962.
Copy Download .nbib Format: NLM
Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90.

European journal of medical genetics

Narayanan DL, Majethia P, Shrikiran A, Siddiqui S, Dalal A, Shukla A.
PMID: 34871784
Eur J Med Genet. 2021 Dec 04;65(1):104403. doi: 10.1016/j.ejmg.2021.104403. Epub 2021 Dec 04.

Developmental and epileptic encephalopathies (DEE) are a genetically heterogeneous group of disorders characterised by early onset epilepsy, epileptiform activity on electroencephalogram and associated developmental delay or neuroregression. With the advent of high throughput sequencing, novel gene-disease associations have been...

Cite
Narayanan DL, Majethia P, Shrikiran A, et al. Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90. Eur J Med Genet. 2021;65(1):104403doi: 10.1016/j.ejmg.2021.104403.
Narayanan, D. L., Majethia, P., Shrikiran, A., Siddiqui, S., Dalal, A., & Shukla, A. (2021). Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90. European journal of medical genetics, 65(1), 104403. https://doi.org/10.1016/j.ejmg.2021.104403
Narayanan, Dhanya Lakshmi, et al. "Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90." European journal of medical genetics vol. 65,1 (2021): 104403. doi: https://doi.org/10.1016/j.ejmg.2021.104403
Narayanan DL, Majethia P, Shrikiran A, Siddiqui S, Dalal A, Shukla A. Further evidence of affected females with a heterozygous variant in FGF13 causing X-linked developmental and epileptic encephalopathy 90. Eur J Med Genet. 2021 Dec 04;65(1):104403. doi: 10.1016/j.ejmg.2021.104403. Epub 2021 Dec 04. PMID: 34871784.
Copy Download .nbib Format: NLM
Safety and efficacy of the new CryoPop® cryotherapy device for cervical dysplasia in low- and middle-income countries: study protocol for a multicenter open-label non-inferiority clinical trial with historical controls.

Trials

Yogeshkumar S, Anderson J, Lu E, Kenyi E, Mensa M, Thaler K, Antartani R, Donimath K, Patil B, Chikaraddi S, Bidri S, Biradar A, Gudadinni MR, Lokare L, Yenokyan G, Bellad MB, Goudar SS, Derman R, Revankar A, Patil H, Wani R, Kangle R, Chavan RY, Nagmoti MB, Kabadi YM, Reddy P, Vernekar S, Hipparagi S, Patil V, Dalal A.
PMID: 34903244
Trials. 2021 Dec 13;22(1):915. doi: 10.1186/s13063-021-05802-8.

BACKGROUND: Cervical cancer is the fourth most common cancer in the world, affecting mainly women residing in low- and middle-income countries. Progression from a pre-invasive phase to that of an invasive phase generally takes years and provides a window...

Cite
Yogeshkumar S, Anderson J, Lu E, et al. Safety and efficacy of the new CryoPop® cryotherapy device for cervical dysplasia in low- and middle-income countries: study protocol for a multicenter open-label non-inferiority clinical trial with historical controls. Trials. 2021;22(1):915doi: 10.1186/s13063-021-05802-8.
Yogeshkumar, S., Anderson, J., Lu, E., Kenyi, E., Mensa, M., Thaler, K., Antartani, R., Donimath, K., Patil, B., Chikaraddi, S., Bidri, S., Biradar, A., Gudadinni, M. R., Lokare, L., Yenokyan, G., Bellad, M. B., Goudar, S. S., Derman, R., Revankar, A., Patil, H., Wani, R., Kangle, R., Chavan, R. Y., Nagmoti, M. B., Kabadi, Y. M., Reddy, P., Vernekar, S., Hipparagi, S., Patil, V., & Dalal, A. (2021). Safety and efficacy of the new CryoPop® cryotherapy device for cervical dysplasia in low- and middle-income countries: study protocol for a multicenter open-label non-inferiority clinical trial with historical controls. Trials, 22(1), 915. https://doi.org/10.1186/s13063-021-05802-8
Yogeshkumar, S, et al. "Safety and efficacy of the new CryoPop® cryotherapy device for cervical dysplasia in low- and middle-income countries: study protocol for a multicenter open-label non-inferiority clinical trial with historical controls." Trials vol. 22,1 (2021): 915. doi: https://doi.org/10.1186/s13063-021-05802-8
Yogeshkumar S, Anderson J, Lu E, Kenyi E, Mensa M, Thaler K, Antartani R, Donimath K, Patil B, Chikaraddi S, Bidri S, Biradar A, Gudadinni MR, Lokare L, Yenokyan G, Bellad MB, Goudar SS, Derman R, Revankar A, Patil H, Wani R, Kangle R, Chavan RY, Nagmoti MB, Kabadi YM, Reddy P, Vernekar S, Hipparagi S, Patil V, Dalal A. Safety and efficacy of the new CryoPop® cryotherapy device for cervical dysplasia in low- and middle-income countries: study protocol for a multicenter open-label non-inferiority clinical trial with historical controls. Trials. 2021 Dec 13;22(1):915. doi: 10.1186/s13063-021-05802-8. PMID: 34903244.
Copy Download .nbib Format: NLM
Showing 409 to 412 of 412 entries